GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (FRA:VM4) » Definitions » Total Inventories

Vanda Pharmaceuticals (FRA:VM4) Total Inventories : €1.4 Mil (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Total Inventories?

Vanda Pharmaceuticals's total inventories for the quarter that ended in Mar. 2024 was €1.4 Mil. Vanda Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was €1.3 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Vanda Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €4.96.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Vanda Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was 37.90.

Inventory Turnover measures how fast the company turns over its inventory within a year. Vanda Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 was 2.41.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Vanda Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.03.


Vanda Pharmaceuticals Total Inventories Historical Data

The historical data trend for Vanda Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Total Inventories Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.03 1.05 0.91 1.13 1.24

Vanda Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.00 0.94 1.24 1.39

Vanda Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Vanda Pharmaceuticals  (FRA:VM4) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Vanda Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

Net-Net Working Capital Per Share (Q: Mar. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(362.611+0.75 * 33.776+0.5 * 1.385-99.992
-0-0)/58.1965
=4.96

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Vanda Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=1.3145/3.165*365 / 4
=37.90

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Vanda Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=3.165 / 1.3145
=2.41

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Vanda Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=1.3145 / 43.665
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Vanda Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (FRA:VM4) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.

Vanda Pharmaceuticals (FRA:VM4) Headlines

No Headlines